Efficacy of wheat-based biscuits fortified with microcapsules containing ferrous sulfate and potassium iodate or a new hydrogen-reduced elemental iron: a randomised, double-blind, controlled trial in Kuwaiti women.
Adverse sensory changes prevent the addition of highly bioavailable ferrous sulfate (FeSO4) to most wheat flours. Poorly absorbable reduced Fe powders are commonly used. Encapsulation of FeSO4 can overcome these sensory changes, but the particle size of commercial compounds is too large to be used by flour mills. The first objective of the study was to measure the efficacy in wheat flour of two newly developed Fe compounds, an H-reduced Fe powder (NutraFine RS; North America Höganäs High Alloys LLC, Johnstown, PA, USA) and small particle-sized (40 microm) encapsulated FeSO4. As a second objective, the microcapsules were evaluated as a vehicle for iodine fortification. A randomised, double-blind controlled intervention trial was conducted in Kuwaiti women (n 279; aged 18-35 years) with low body Fe stores (serum ferritin (SF) < 25 microg/l) randomly assigned to one of three groups (20 mg Fe as NutraFine RS, 10 mg Fe as encapsulated FeSO4 and 150 microg iodine, or no fortification Fe) who consumed wheat-based biscuits 5 d per week. At baseline and 22 weeks, Hb, SF, transferrin receptor, urinary iodine and body Fe stores were measured. Relative to control, mean SF in the encapsulated FeSO4 group increased by 88 % (P < 0.001) and body Fe stores increased from - 0.96 to 2.24 mg/kg body weight (P < 0.001), while NutraFine RS did not significantly increase SF or body Fe stores. The median urinary iodine concentration increased from 140 to 213 microg/l (P < 0.01). NutraFine RS added at double the amount of Fe as FeSO4 was not efficacious in improving Fe status. The newly developed microcapsules were highly efficacious in improving both Fe stores and iodine status.
Biebinger
Ralf
R
The Human Nutrition Laboratory, Institute of Food Science and Nutrition, ETH Zurich, Zurich, Switzerland.
Zimmermann
Michael B
MB
Al-Hooti
Suad N
SN
Al-Hamed
Nawal
N
Al-Salem
Ebtehal
E
Zafar
Tasleem
T
Kabir
Yearul
Y
Al-Obaid
I'nam
I
Petry
Nicolai
N
Hurrell
Richard F
RF
D000293:Adolescent; D000328:Adult; D002214:Capsules; D004311:Double-Blind Method; D005260:Female; D005296:Ferrous Compounds / Q000008:administration & dosage*; D005524:Food Technology / Q000379:methods; D005527:Food, Fortified; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007452:Iodates / Q000008:administration & dosage*; D007501:Iron / Q000378:metabolism; D019266:Iron, Dietary / Q000008:administration & dosage*; D007730:Kuwait; D010084:Oxidation-Reduction; D010316:Particle Size; D017680:Potassium Compounds / Q000008:administration & dosage*; D012995:Solubility; D013649:Taste; D014168:Transferrin / Q000378:metabolism; D014908:Triticum / Q000737:chemistry*; D014961:X-Ray Diffraction; D055815:Young Adult
D002214:Capsules; D005296:Ferrous Compounds; D006454:Hemoglobins; D007452:Iodates; D019266:Iron, Dietary; D017680:Potassium Compounds; D014168:Transferrin; C020748:ferrous sulfate; D007501:Iron; C039693:potassium iodate